Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA Congress
Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN
Strong balance sheet expected to fund operations to early 2026
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.